"Receptors, CCR4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
CCR receptors with specificity for CHEMOKINE CCL17 and CHEMOKINE CCL22. They are expressed at high levels in T-LYMPHOCYTES; MAST CELLS; DENDRITIC CELLS; and NK CELLS.
| Descriptor ID |
D054398
|
| MeSH Number(s) |
D12.776.543.750.695.160.150.400 D12.776.543.750.705.852.125.150.400
|
| Concept/Terms |
Receptors, CCR4- Receptors, CCR4
- CC Chemokine Receptor 4
- CCR4 Receptor
- Receptor, CCR4
- Antigens, CD194
- CCR4 Receptors
- CD194 Antigens
- CC Chemokine Receptors 4
- CD194 Antigen
- Antigen, CD194
|
Below are MeSH descriptors whose meaning is more general than "Receptors, CCR4".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Chemokine [D12.776.543.750.695.160]
- Receptors, CCR [D12.776.543.750.695.160.150]
- Receptors, CCR4 [D12.776.543.750.695.160.150.400]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Chemokine [D12.776.543.750.705.852.125]
- Receptors, CCR [D12.776.543.750.705.852.125.150]
- Receptors, CCR4 [D12.776.543.750.705.852.125.150.400]
Below are MeSH descriptors whose meaning is more specific than "Receptors, CCR4".
This graph shows the total number of publications written about "Receptors, CCR4" by people in this website by year, and whether "Receptors, CCR4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 2 | 3 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, CCR4" by people in Profiles.
-
Small-Molecule CCR4 Antagonists in Cutaneous T-cell Lymphoma. Cancer Res Commun. 2024 Oct 01; 4(10):2756-2765.
-
Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clin Microbiol Infect. 2022 Oct; 28(10):1321-1327.
-
Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 02; 21(2):97-105.
-
Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. Clin Cancer Res. 2020 09 01; 26(17):4531-4541.
-
De Novo Variants in CNOT1, a Central Component of the CCR4-NOT Complex Involved in Gene Expression and RNA and Protein Stability, Cause Neurodevelopmental Delay. Am J Hum Genet. 2020 07 02; 107(1):164-172.
-
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and S?zary Syndrome. Clin Cancer Res. 2019 12 15; 25(24):7275-7280.
-
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. Cancer Cell. 2019 08 12; 36(2):139-155.e10.
-
Antibody-Based Therapies for Cutaneous T-Cell Lymphoma. Am J Clin Dermatol. 2019 Feb; 20(1):115-122.
-
Differential expression of CCR4 in primary cutaneous gamma/delta (?/d) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. J Dermatol Sci. 2018 Jan; 89(1):88-91.
-
Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma. Expert Rev Hematol. 2017 09; 10(9):757-760.